Skip to content

Dyspepsia and indigestion on Zepbound, Wegovy, Mounjaro and other GLP-1 medicines

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Zepbound indigestion, which the label calls dyspepsia, was reported by 9% to 10% of adults against 4% on placebo. Dyspepsia is in the tables of six GLP-1 labels, including 9% on Wegovy 2.4 mg against 3%. The Ozempic and Rybelsus labels report it in text, below their table cutoff. Tell your prescriber about indigestion that persists or follows each dose increase.

Key takeaways

  • Dyspepsia is the label word for indigestion. Six GLP-1 labels list it in their tables.
  • Tell your prescriber if indigestion or bloating persists, worsens after a dose increase, or limits what you eat and drink.
  • Seek prompt medical attention for severe or persistent abdominal pain.
  • Ask a pharmacist before taking an antacid or acid reducer alongside your other medicines.

How often it was reported in the label's trials

Zepbound: Table 1: Adverse Reactions (≥2% and Greater than Placebo) in ZEPBOUND-Treated Adults with Obesity or Overweight in Weight Reduction and Long-term Maintenance Trials (Study 1 and Study 2) · Pool of two randomized, double-blind, placebo-controlled weight reduction trials (Study 1 and Study 2) that included 2,519 adults with obesity or overweight, with or without type 2 diabetes, treated with Zepbound for up to 72 weeks plus a 4-week off-drug follow-up period.
ReactionPlacebon=9585 mgn=63010 mgn=94815 mgn=941
Dyspepsia4%9%9%10%

FDA label: Zepbound, Revised: 8/2026 (DailyMed version 40)

Mounjaro: Table 1: Adverse Reactions in Pool of Placebo-Controlled Trials Reported in ≥5% of MOUNJARO-treated Adult Patients with Type 2 Diabetes Mellitus · Pool of two placebo-controlled trials in adults with type 2 diabetes (SURPASS-1 monotherapy and SURPASS-5 added to basal insulin with or without metformin); 718 patients exposed to Mounjaro for a mean of 36.6 weeks. Hypoglycemia is not included.
ReactionPlacebon=2355 mgn=23710 mgn=24015 mgn=241
Dyspepsia3%8%8%5%

FDA label: Mounjaro, Revised: 8/2026 (DailyMed version 40)

Wegovy: Table 3. Adverse Reactions (≥2% and Greater Than Placebo) in WEGOVY 2.4 mg Injection-treated Adults with Obesity or Overweight for Weight Reduction · Adults with obesity or overweight in 3 randomized, double-blind, placebo-controlled trials, treated with Wegovy 2.4 mg injection for up to 68 weeks plus a 7-week off-drug follow-up. The label shows '<1' for placebo eructation. The hypoglycemia row is for patients with type 2 diabetes not on insulin (Study 3: Wegovy N=403, placebo N=402). Abdominal pain, fatigue, gastritis and dysesthesia are grouped terms.
ReactionPlacebon=1261Wegovy injection 2.4 mg once weeklyn=2116
Dyspepsia3%9%

FDA label: Wegovy, Revised: 6/2026 (DailyMed version 19)

Foundayo: Table 1: Adverse Reactions Reported in ≥5% of FOUNDAYO-treated Adult Patients with Obesity or Overweight (With or Without Type 2 Diabetes) in Pool of Placebo-Controlled Trials (Trials 1 and 2) · Pool of two randomized, double-blind, placebo-controlled weight management trials (Trials 1 and 2) that included 3155 adults with obesity or overweight, with or without type 2 diabetes, treated with Foundayo once daily for up to 72 weeks plus a 2-week off-drug follow-up period.
ReactionPlacebon=15765.5 mgn=10519 mgn=105517.2 mgn=1049
Dyspepsia4%12%16%13%

FDA label: Foundayo, Revised: 7/2026 (DailyMed version 10)

Saxenda: Table 2. Adverse Reactions Occurring in ≥2% of SAXENDA-treated Adult Patients and More Frequently than Placebo · Adults with overweight or obesity in 5 double-blind, placebo-controlled trials, treated for up to 56 weeks (3 trials), 52 weeks (1 trial) and 32 weeks (1 trial). The hypoglycemia row is for patients with type 2 diabetes not on insulin (Study 2: Saxenda N=423, placebo N=212), defined as blood glucose below 54 mg/dL with or without symptoms.
ReactionPlacebon=1941Saxendan=3384
Dyspepsia2.7%9.6%
Saxenda: Table 3. Adverse Reactions Occurring in ≥3% of SAXENDA-treated Pediatric Patients and More Frequently than Placebo in a 56 Week Clinical Trial · Pediatric patients aged 12 years and older with obesity, without type 2 diabetes, in a 56-week placebo-controlled trial. The hypoglycemia row is defined as blood glucose below 70 mg/dL with symptoms.
ReactionPlacebon=126Saxendan=125
Dyspepsia2.4%4%

FDA label: Saxenda, Revised: 6/2026 (DailyMed version 22)

Trulicity: Table 1: Adverse Reactions in Pool of Placebo-Controlled Trials That Occurred in ≥5% of TRULICITY-Treated Adult Patients with Type 2 Diabetes Mellitus · Pool of placebo-controlled trials that included 1,670 adults with type 2 diabetes exposed to Trulicity 0.75 mg or 1.5 mg, with a mean duration of exposure of 23.8 weeks. Hypoglycemia is excluded.
ReactionPlacebon=5680.75 mgn=8361.5 mgn=834
Dyspepsia2.3%4.1%5.8%
Trulicity: Table 2: Adverse Reactions That Occurred in ≥5% of TRULICITY-treated Adult Patients with Type 2 Diabetes Mellitus in a Clinical Trial through 36 Weeks · Clinical trial of 1842 adults with type 2 diabetes treated with Trulicity 1.5 mg, 3 mg, or 4.5 mg once weekly as add-on to metformin, through 36 weeks (no placebo arm).
Reaction1.5 mgn=6123 mgn=6164.5 mgn=614
Dyspepsia2.8%5%2.6%

FDA label: Trulicity, Revised: 3/2026 (DailyMed version 62)

Each medicine's figures come from its own trials, which differ in dose, length and who took part. They are not a head-to-head comparison.

If you have indigestion, reflux or bloating on a GLP-1 medicine, tell your prescriber if it persists, if it worsens after a dose increase, or if it affects how much you can eat and drink. Seek prompt medical attention for severe or persistent abdominal pain.

Dyspepsia is the label word for indigestion. Six of the eight GLP-1 labels give it a row in their tables of common reactions, and the other two report it in text. The labels also list several close relatives (reflux, burping, bloating and gas) as separate rows, covered below.

Labels that list dyspepsia in their tables

Each figure is the share of trial patients who reported dyspepsia, next to the placebo group from the same trials. A placebo group gets an inactive treatment instead of the medicine.

  • Foundayo (adults with obesity or overweight, two pooled trials): 12% at 5.5 mg, 16% at 9 mg and 13% at 17.2 mg, with 4% on placebo.
  • Zepbound (adults with obesity or overweight, two pooled trials): 9% at 5 mg, 9% at 10 mg and 10% at 15 mg, with 4% on placebo.
  • Saxenda (adults, five trials): 9.6%, with 2.7% on placebo. In adolescents aged 12 and older: 4%, with 2.4% on placebo.
  • Wegovy 2.4 mg injection (adults, three weight reduction trials): 9%, with 3% on placebo.
  • Mounjaro (adults with type 2 diabetes, two pooled trials): 8% at 5 mg, 8% at 10 mg and 5% at 15 mg, with 3% on placebo.
  • Trulicity (adults with type 2 diabetes, pooled trials): 4.1% at 0.75 mg and 5.8% at 1.5 mg, with 2.3% on placebo. In the higher-dose trial with no placebo arm: 2.8% at 1.5 mg, 5.0% at 3 mg and 2.6% at 4.5 mg.

The highest dose group doesn’t always have the highest figure. In Mounjaro’s table, Foundayo’s and Trulicity’s higher-dose trial, a lower or middle group reported more dyspepsia than the top one. The labels don’t comment on this.

Dyspepsia isn’t listed in Wegovy’s table for the 7.2 mg dose, which includes only reactions more frequent on 7.2 mg than on both 2.4 mg and placebo. It isn’t in Wegovy’s adolescent table either.

Labels that report it below the table cutoff

Ozempic. The injection label’s table is limited to reactions reported by at least 5% of patients. Its text adds gastrointestinal (stomach and bowel) reactions with a frequency under 5%, listed as placebo, 0.5 mg and 1 mg: dyspepsia at 1.9%, 3.5% and 2.7%.

Rybelsus. The tablet label, which also covers Ozempic tablets, likewise lists dyspepsia among the gastrointestinal reactions that fall outside its table, each reported by 3% of patients or fewer. Dyspepsia isn’t listed in the Rybelsus table itself.

Reflux, burping, bloating and gas

Indigestion rarely arrives alone in these tables. The same labels report these as separate rows. Eructation is burping, flatulence is gas, abdominal distension is bloating, and reflux here means gastroesophageal reflux disease.

  • Zepbound: gastroesophageal reflux disease at 4%, 4% and 5% across the 5 mg, 10 mg and 15 mg groups, with 2% on placebo; eructation at 4%, 5% and 5%, with 1% on placebo; flatulence and abdominal distension each at 3%, 3% and 4%, with 2% on placebo.
  • Wegovy 2.4 mg: abdominal distension 7% (5% on placebo), eructation 7%, flatulence 6% (4%), reflux 5% (3%) and gastritis 4% (1%). For eructation the label shows the placebo figure only as below 1%.
  • Foundayo: abdominal distension at 7%, 9% and 8% across its three dose groups, with 3% on placebo; eructation at 6%, 8% and 8%, with 1%; reflux at 6%, 6% and 7%, with 2%.
  • Saxenda: reflux 4.7% (1.7% on placebo), eructation 4.5% (0.2%), abdominal distension 4.5% (3%) and flatulence 4% (2.5%).
  • Mounjaro, in text, as placebo, 5 mg, 10 mg and 15 mg: eructation 0.4%, 3.0%, 2.5% and 3.3%; reflux 0.4%, 1.7%, 2.5% and 1.7%.
  • Trulicity, in text, as placebo, 0.75 mg and 1.5 mg: reflux 0.5%, 1.7% and 2.0%; eructation 0.2%, 0.6% and 1.6%.

These rows overlap in the people they count, and the trials behind each label are separate. Read each medicine against its own placebo column. The figures don’t rank the medicines.

The labels’ timing statements are about nausea, vomiting and diarrhea. Only Wegovy’s is wide enough to include dyspepsia: gastrointestinal reactions as a group “were most frequently reported during dosage escalation,” the weeks when the dose is being raised.

Every label warns that gastrointestinal reactions are sometimes severe and says the medicine is not recommended in people with severe gastroparesis (a stomach that empties very slowly). In Zepbound’s pooled trials, severe gastrointestinal reactions were reported by 1.7% of patients on 5 mg, 2.5% on 10 mg and 3.1% on 15 mg, against 1% on placebo.

Upper abdominal discomfort also overlaps with the symptom the labels use to describe pancreatitis, an inflammation of the pancreas: persistent or severe abdominal pain, sometimes radiating to the back. Indigestion that’s mild and comes and goes is what the tables describe. Pain that’s severe or doesn’t let up is a different matter, covered on the abdominal pain page.

When to contact your prescriber

Raise indigestion, reflux or bloating with your prescriber if it persists, if it worsens after a dose increase, or if it affects how much you can eat and drink. Seek prompt medical attention for severe or persistent abdominal pain. Leave dose decisions to your prescriber.

See also nausea, constipation and the side effects overview.

Frequently asked questions

What is dyspepsia?

Dyspepsia is the word the FDA labels use for indigestion, meaning discomfort in the upper abdomen around eating. The labels list it as its own row, separate from abdominal pain, gastroesophageal reflux disease (heartburn), eructation (burping), flatulence (gas) and abdominal distension (bloating). One person can report several of these, so you can't add the rows together.

Does Mounjaro cause indigestion?

Yes, dyspepsia is in the Mounjaro label's table. In two pooled placebo-controlled trials in adults with type 2 diabetes, 8% of patients on 5 mg, 8% on 10 mg and 5% on 15 mg reported it, compared with 3% on placebo. The label also reports burping, gas, reflux and bloating more often on Mounjaro than on placebo.

Does Ozempic cause heartburn or indigestion?

The Ozempic injection label reports both, below its table's cutoff. Dyspepsia was reported by 3.5% of patients on 0.5 mg and 2.7% on 1 mg, against 1.9% on placebo. Gastroesophageal reflux disease was reported by 1.9% and 1.5%, against 0% on placebo. These figures come from placebo-controlled trials in adults with type 2 diabetes.

When is indigestion on a GLP-1 a reason to call?

Tell your prescriber about indigestion that persists or follows each dose increase. Seek prompt medical attention for persistent or severe abdominal pain, sometimes radiating to the back, with or without vomiting, because the labels describe that as a sign of acute pancreatitis. Ask a pharmacist before taking an antacid or acid reducer alongside your other medicines.

Sources (8)

  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.